Researchers has substantially boosted its progress of the new solution for cardiac amyloidosis, leveraging the compound. Initial clinical results reveals significant improvements for individuals diagnosed with a debilitating illness. The emphasis underscores BridgeBio's dedication to managing significant patient requirements in this heart arena. A